Rhenium-186 hydroxyethylidene diphosphonate for treatment of painful osseous metastases from mammary carcinoma

Tumori. 1997 Mar-Apr;83(2):563-5. doi: 10.1177/030089169708300218.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Blood Platelets / radiation effects
  • Bone Marrow / radiation effects*
  • Bone Neoplasms / complications
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / radiotherapy*
  • Bone Neoplasms / secondary*
  • Bone Neoplasms / urine
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / urine
  • Etidronic Acid / adverse effects
  • Etidronic Acid / pharmacokinetics
  • Etidronic Acid / therapeutic use*
  • Female
  • Humans
  • Leukocytes / radiation effects
  • Middle Aged
  • Organometallic Compounds
  • Pain / etiology*
  • Pain Measurement
  • Radioisotopes / adverse effects
  • Radioisotopes / pharmacokinetics
  • Radioisotopes / therapeutic use*
  • Rhenium / adverse effects
  • Rhenium / pharmacokinetics
  • Rhenium / therapeutic use*
  • Treatment Outcome

Substances

  • Organometallic Compounds
  • Radioisotopes
  • rhenium-186 HEDP
  • Rhenium
  • Etidronic Acid